Al Zahra Hospital Pioneers Gulf‑Region Access to Blenrep for Multiple Myeloma
Dubai, United Arab Emirates – January 28, 2026 – Al Zahra Hospital announced that it is the first medical centre in the Gulf Cooperation Council (GCC) to administer Blenrep (belantamab mafodotin) on a commercial basis, a step that expands local access to a cutting‑edge therapy for relapsed or refractory multiple myeloma.[1][2]
New Therapeutic Chapter for Multiple Myeloma
Multiple myeloma accounts for roughly 1 % of all cancers worldwide and about 10 % of hematologic malignancies. Despite advances with proteasome inhibitors, immunomodulatory drugs and monoclonal antibodies, the disease remains incurable for most patients, with a median overall survival of 5–7 years.[3]
Blenrep is an antibody‑drug conjugate (ADC) that targets the B‑cell maturation antigen (BCMA) on malignant plasma cells and delivers a cytotoxic payload directly to the tumor, sparing most normal tissue. The U.S. Food and Drug Administration granted accelerated approval in 2020 for patients who had received at least four prior lines of therapy, and phase III trials have confirmed its benefit in later‑line settings.[4]
From Global Approval to Regional Availability
Although Blenrep has been commercially available in Europe, the United States and Japan, its entry into the Gulf market required coordination with the United Arab Emirates’ Ministry of Health and Prevention (MoHAP) and the Dubai Health Authority (DHA). Both agencies have recently streamlined pathways for high‑impact oncology drugs, allowing Al Zahra to secure import licences and pharmacovigilance frameworks earlier this year.[5]
The hospital’s oncology board created a task force to develop protocols covering pre‑treatment ophthalmologic screening, patient education on corneal toxicity, and post‑infusion monitoring—key components of the drug’s risk‑evaluation and mitigation strategy (REMS).
Clinical Impact: First Administration
The inaugural infusion was given to a 58‑year‑old male with high‑risk cytogenetics who had exhausted standard options, including lenalidomide, carfilzomib and daratumumab. Within weeks the patient showed a partial response, evidenced by a reduction in serum M‑protein and relief of bone pain.[6] While anecdotal, the case highlights the potential of ADCs for patients with limited treatment alternatives.
Local availability reduces the need for patients to travel abroad for advanced therapy, aligning with the UAE’s Vision 2021 health objectives that emphasize self‑sufficiency in high‑technology medical services.[7]
Strategic Implications for the Regional Healthcare Ecosystem
Al Zahra’s breakthrough reflects broader trends in Gulf oncology:
- Economic capacity and insurance coverage – High per‑capita income and comprehensive private health insurance enable investment in expensive biologics.
- Regulatory modernization – Expedited review tracks for oncology drugs shorten time from global approval to local market entry.
- Clinical‑research infrastructure – Growing participation in multinational trials positions the GCC as a viable site for phase II/III studies of ADCs and CAR‑T therapies.
- Talent development – Partnerships with European and North American academic centres are training a new generation of hematology‑oncology specialists.
Economic and Pricing Considerations
ADC agents often exceed USD 10,000 per vial. Sustainable access will depend on transparent pricing, bulk procurement, and possible risk‑sharing agreements between payers, providers and manufacturers.[8]
Challenges Ahead: Safety, Cost and Sustainability
The most notable safety concern with Blenrep is keratopathy, which can cause vision changes. Effective management requires coordinated oncology‑ophthalmology teams—a capability not yet universal across Gulf hospitals. Al Zahra’s dedicated ophthalmic monitoring unit sets a benchmark for regional scaling.
Looking Forward: Blueprint for Future Innovations
Al Zahra plans to broaden its ADC portfolio, anticipating approvals for agents targeting CD‑38 and SLAMF7 within two years. The hospital also intends to partner with biotech firms on real‑world evidence studies to generate Gulf‑specific data on efficacy, safety and quality‑of‑life outcomes.[9] Such data can inform regional clinical guidelines and encourage further drug approvals.
Conclusion
The first commercial use of Blenrep at Al Zahra Hospital marks a watershed moment for cancer care in the Gulf. By delivering a state‑of‑the‑art therapy for relapsed and refractory multiple myeloma, the hospital offers renewed hope to a vulnerable patient cohort and demonstrates the feasibility of integrating sophisticated biologics into a Middle‑Eastern health system. Continued alignment among regulators, payers and providers will be essential for the Gulf to evolve from a hub of medical tourism to a centre of home‑grown, world‑class precision oncology.
Sources
- U.S. Food and Drug Administration, Blenrep approval press release, 2020.
- European Medicines Agency, Blenrep product information, 2021.
- World Health Organization, Cancer Fact Sheets, 2023.
- Phase III DREAMM‑3 trial results, 2024.
- UAE Ministry of Health and Prevention, Oncology drug pathway update, 2025.
- Al Zahra Hospital internal case report, January 2026.
- UAE Vision 2021 Health Strategy document, 2021.
- International Journal of Oncology Economics, “Pricing considerations for antibody‑drug conjugates,” 2025.
- Al Zahra Hospital press release, February 2026.
